MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

Blood Cancer Journal

Volumn 3, Issue 3, 2013, Pages

  Leow, C Chang Yew ^a   Gerondakis, S ^a   Spencer, A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

MEK; MEK inhibitors; Multiple myeloma; Ras MAPK

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BAY 8679655; BAY 869766; BORTEZOMIB; COBIMETINIB; CYTARABINE; DOCETAXEL; DOXORUBICIN; GEFITINIB; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MSC 1935369; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PICTILISIB; PIMASERTIB; SELUMETINIB; THALIDOMIDE; TRAMETINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CELL DEATH; CLINICAL EVALUATION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NEUROTOXICITY; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84878311335     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.1     Document Type: Review

References (100)

1. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290. (Pubitemid 46763021)
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284. (Pubitemid 47125967)
3. Morabito F, Gentile M, Mazzone C, Bringhen S, Vigna E, Lucia E et al. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. Eur J Haematol 2010; 85: 181-191.
4. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028. (Pubitemid 44395016)
5. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598. (Pubitemid 47106630)
6. Malumbres M, Barbacid M. RAS oncogenes: The first 30 years. Nat Rev Cancer 2003; 3: 459-465. (Pubitemid 37328850)
7. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654. (Pubitemid 24036012)
8. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-822. (Pubitemid 29080340)
9. Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 1995; 15: 6430-6442.
10. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. J Biol Chem 1997; 272: 4378-4383. (Pubitemid 27078513)
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
12. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-362. (Pubitemid 43128863)
13. Bonello L, Voena C, Ladetto M, Boccadoro M, Palestro G, Inghirami G et al. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia 2003; 17: 2238-2240. (Pubitemid 37428395)
14. Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74(raf-1). EMBO J 1994; 13: 1610-1619.
15. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD et al. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-675.
16. Yoon S, Seger R. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24: 21-44. (Pubitemid 43108774)
17. Kim HJ, Bar-Sagi D. Modulation of signalling by sprouty: A developing story. Nat Rev Mol Cell Biol 2004; 5: 441-450. (Pubitemid 38745494)
18. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 27: 253-261.
19. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB J 2000; 14: 6-16. (Pubitemid 30051518)
20. Udell CM, Rajakulendran T, Sicheri F, Therrien M. Mechanistic principles of RAF kinase signaling. Cell Mol Life Sci 2011; 68: 553-565.
21. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, De Matos Simoes R, Carugo O et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 2009; 16: 294-303.
22. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729-736. (Pubitemid 32113407)
23. Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L et al. Ras oncogene mutation in multiple myeloma. J Exp Med 1989; 170: 1715-1725. (Pubitemid 19284568)
24. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group phase III trial. Blood 1996; 88: 2699-2706. (Pubitemid 26327523)
25. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212-224. (Pubitemid 32807900)
26. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580. (Pubitemid 44118772)
27. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008; 22: 2280-2284.
28. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IMS. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317-323. (Pubitemid 40053099)
29. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B et al. P13-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890. (Pubitemid 39530020)
30. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712-3721. (Pubitemid 39564449)
31. Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci USA 1993; 90: 2251-2255. (Pubitemid 23078604)
32. Gantke T, Sriskantharajah S, Sadowski M, Ley SC. IkB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 2012; 246: 168-182.
33. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004; 23: 5301-5315. (Pubitemid 39005806)
34. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248-1252. (Pubitemid 40946011)
35. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811-18816. (Pubitemid 36799262)
36. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11: 1192-1197.
37. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-7689.
38. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-18632. (Pubitemid 28334795)
39. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-816. (Pubitemid 29318616)
40. LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293. (Pubitemid 46206982)
41. Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-4462. (Pubitemid 41185111)
42. Brown AP, Carlson TCG, Loi CM, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 2007; 59: 671-679. (Pubitemid 46295133)
43. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16: 1924-1937.
44. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 2450-2457.
45. Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009; 25: 519-530.
46. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6: 2209-2219. (Pubitemid 47294749)
47. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 13: 1576-1583. (Pubitemid 46450450)
48. Huynh H, Soo KC, Chow PKH, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007; 6: 138-146. (Pubitemid 46206676)
49. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-2146.
50. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. JThorac Oncol 2010; 5: 1630-1636.
51. Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 25: 1021-1028.
52. O'Neil BH, Goff LW, Kauh JSW, Strosberg JR, Bekaii-Saab TS, Lee RM et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011; 29: 2350-2356.
53. Goutopoulos A, Askew B, Bankston D, Clark A, Dhanabal M, Dong R et al. AS703026: A novel allosteric MEK inhibitor. In: 100th Annual Meeting of the American Association for Cancer Research 2009; (Abstract [4776]).
54. Awada A, Houede N, Delord JP, Dubuisson M, Italiano A, Berge Y et al. Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors. In: 22nd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics 2010; (Abstract [374]).
55. Johnston S. XL518, a potent selective orally bioavailable MEK1 inhibitor, downregulates the RAS/RAF/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in pre-clinical models. In: 20th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics 2007; (Abstract [C209]).
56. Rosen L, LoRusso P, Wee W, Goldman J, Weise A, Colevas AD et al. A first-inhuman phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. In: 102nd Annual Meeting of the American Association for Cancer Research 2011; (Abstract [3611]).
57. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P et al. RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009; 69: 6839-6847.
58. Weekes C, Von Hoff DD, Adjei AA, Yeh LT, Leffingwell D, Sheedy B et al. A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/ pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients. In: 22nd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics 2010; (Abstract [109]).
59. Gilmartin AG, Kusnlerx AM, Sutton D, Moss KG, Thompson CS, Weber BL et al. GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models. In: 20th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics 2008; (Abstract [567]).
60. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 989-1000.
61. Gordon MS, Infante JR, Messersmith LA, Vogelzang NJ, Cox D, DeMarini DJ et al. The oral MEK1/MEK2 inhibitor, GSK1120212, effectively inhibits the MAPK pathway: Pharmacokinetic, pharmacodynamic, and clinical response relationship. In: 22nd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics 2010; (Abstract [373]).
62. Borthakur G, Popplewell L, Kirschbaum MH, Foran JM, Kadia TM, Jabbour E et al. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation [abstract]. J Clin Oncol 2011; 29(suppl): Abstr 6506.
63. Huynh H, Chow PKH, Soo KC. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 2007; 6: 2468-2476. (Pubitemid 47480412)
64. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008; 14: 230-239. (Pubitemid 351378000)
65. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis 2009; 14: 1108-1120.
66. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EWT, Steelman LS et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008; 22: 2080-2090.
67. Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxelmediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 2001; 60: 143-154. (Pubitemid 32595242)
68. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Science Signaling 2011; 4: 166.
69. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signaling 2010; 3: 149.
70. Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-Raf V600E mutation. Cancer Res 2011; 71: 5535-5545.
71. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: Physiological feedback and drug response. Clin Cancer Res 2010; 16: 3329-3334.
72. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Milano) 2011; 3: 192-222.
73. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009; 125: 2332-2341.
74. Yoon YK, Kim HP, Han SW, Hur HS, Do YO, Im SA et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009; 8: 2526-2536.
75. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
76. Bendell J, LoRusso P, Kwak E, Pandya S, Musib L, Jones C et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A firstin-human phase Ib study in patients with advanced solid tumors. In: 102nd Annual Meeting of the American Association for Cancer Research 2011; (Abstract [LB-89]).
77. Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulos KP, Smith DA et al. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol 2011; 29(suppl): Abstr 3085.
78. Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Mol Carcinog 2010; 49: 353-362.
79. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 2011; 71: 3658-3668.
80. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia: Official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2009; 23: 2222-2232.
81. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
82. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. The Lancet 2010; 376: 2075-2085.
83. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
84. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007; 110: 1656-1663. (Pubitemid 47443984)
85. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D et al. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol 2007; 139: 55-63. (Pubitemid 47389922)
86. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010; 149: 537-549.
87. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062. (Pubitemid 36857886)
88. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784. (Pubitemid 44348499)
89. Wolf JL, Siegel D, Jeffrey M, Lonial S, Goldschmidt H, Schmitt S et al. A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. In: 50th ASH Annual Meeting and Exposition 2008; (Abstract [2774]).
90. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117: 336-342.
91. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011; 35: 373-379.
92. Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández- Lázaro D et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010; 95: 794-803.
93. Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL? human leukemia cells. Leukemia 2005; 19: 1579-1589. (Pubitemid 43090402)
94. Ozaki Ki, Kosugi M, Baba N, Fujio K, Sakamoto T, Kimura S et al. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun 2010; 391: 1610-1615.
95. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Current Opinion in Drug Discovery and Development 2006; 9: 483-495. (Pubitemid 44081157)
96. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092-1100. (Pubitemid 43156310)
97. Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011; 10: 1909-1917.
98. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010; 70: 2264-2273.
99. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. Amechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396-2404.
100. Zingone A, Korde N, Chen J, Xi L, Raffled M, Holkova B et al. Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study. In: 53rd ASH Annual Meeting and Exposition 2011; (Abstract [306]).